Intimate partner violence (IPV) in male and female orthopaedic trauma patients:a multi-centre, cross-sectional prevalence study by Downie, Samantha et al.
                                                                    
University of Dundee
Intimate partner violence (IPV) in male and female orthopaedic trauma patients










Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Downie, S., Kanya, I., Madden, K., Bhandari, M., & Jariwala, A. C. (2021). Intimate partner violence (IPV) in
male and female orthopaedic trauma patients: a multi-centre, cross-sectional prevalence study. BMJ Open,
11(8), [e046164]. https://doi.org/10.1136/bmjopen-2020-046164
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 27. Sep. 2021
1Downie S, et al. BMJ Open 2021;11:e046164. doi:10.1136/bmjopen-2020-046164
Open access 
Intimate partner violence (IPV) in male 
and female orthopaedic trauma patients: 
a multicentre, cross- sectional 
prevalence study
Samantha Downie,1,2 Iuliana Kanya,1 Kim Madden   ,3 Mohit Bhandari,3 
Arpit C Jariwala1,2
To cite: Downie S, Kanya I, 
Madden K, et al.  Intimate 
partner violence (IPV) in male 
and female orthopaedic 
trauma patients: a 
multicentre, cross- sectional 
prevalence study. BMJ Open 
2021;11:e046164. doi:10.1136/
bmjopen-2020-046164
 ► Prepublication history and 
additional supplemental material 
for this paper are available 
online. To view these files, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjopen- 2020- 046164).
Received 21 October 2020
Accepted 08 June 2021
1Orthopaedics Department, NHS 
Tayside, Dundee, UK
2University Department of 
Orthopaedics and Trauma 
Surgery, University of Dundee, 
Dundee, UK
3Department of Surgery, 
McMaster University, Hamilton, 
Ontario, Canada
Correspondence to
Mrs Samantha Downie;  
 samantha. downie3@ nhs. scot
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Objectives Identify the proportion of patients attending 
fracture clinics who had suffered intimate partner violence 
(IPV) within the past year.
Design Powered cross- sectional study using validated 
participant self- reported questionnaires.
Setting and participants Adult trauma patients (no 
gender/age exclusions) attending one of three Scottish 
adult fracture clinics over 16- month period (from October 
2016 to January 2018).
Primary outcome measure Number of participants 
answering ‘yes’ to the Woman Abuse Screening Tool 
question: ‘In your current relationship over the past twelve 
months, has your partner ever abused you physically/
emotionally/sexually?’
Results Of 336 respondents, 46% (156/336 known) were 
women with 65% aged over 40 (212/328 known). The 
overall prevalence of IPV within the preceding 12 months 
was 12% 39/336) for both male and female patients. The 
lifetime prevalence of IPV among respondents was 20% 
(68/336). 38% of patients who had experienced IPV within 
the past 12 months had been physically abused (11/29). 
None of the patients were being seen for an injury caused 
by abuse. Two- thirds of respondents thought that staff 
should ask routinely about IPV (55%, 217/336), but only 
5% had previously been asked about abuse (18/336).
Conclusions This is the first study worldwide 
investigating the prevalence of IPV in fracture clinics for 
both male and female patients. 12- month prevalence of 
IPV in fracture clinic patients is significant and not affected 
by gender in this study. Patients appear willing to disclose 
abuse within this setting and are supportive of staff asking 
about abuse. This presents an opportunity to identify those 
at risk within this vulnerable population.
INTRODUCTION
Approximately one in three women and 
one in six men have experienced intimate 
partner violence (IPV or domestic abuse) 
during their lives.1 Recent estimates of 
current abuse (ie, from a current partner 
within the past 12 months) suggest that IPV 
can affect 8% of women and 4% of men at 
any one time.2
Guidance from the National Institute for 
Clinical Excellence in the UK recommends 
that it is the role of all frontline health-
care staff to identify and help those experi-
encing abuse.1 This does not only include 
those presenting to healthcare with injuries 
resulting from abuse but also identifying 
those with risk factors for IPV and providing 
them with appropriate support and privacy 
and trained staff to action any disclosures of 
abuse.
Historically, research has highlighted the 
role of emergency department (ED) in iden-
tifying vulnerable patients and has focused 
primarily on female patients experiencing 
IPV.1 3 4 Studies indicate that patients find 
screening to be acceptable in the acute care 
setting but that screening should include all 
patients, including men, and not be seen to 
‘select out’ high- risk individuals.4–6 Patients 
experiencing IPV are more likely to disclose 
this if they are asked directly,7 and there is 
Strengths and limitations of this study
 ► This is an inclusive, multicentre study that is pow-
ered to detect 12- month prevalence of intimate 
partner violence (IPV) in male and female patients 
within a trauma population in Scotland.
 ► Questionnaires were completed anonymous-
ly, which helped to protect participant safety and 
confidentiality.
 ► The study was designed with significant input from a 
regional ethics committee and patient and public in-
volvement group, helping to protect and include this 
vulnerable patient population in research.
 ► Participants were asked whether healthcare staff 
had ever discussed IPV with them to validate results 
from a previous study from the perspective of staff 
in the trauma clinic.
 ► To protect anonymity, no prior screening of clinics 
was undertaken, and therefore, minimal data on re-
sponse rates are available.
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some suggestion that disclosure rates are higher with 
questionnaire- based studies rather than via face- to- face 
interviews.4 8
However, the majority of patients in the UK are seen 
and discharged from the ED in under 4 hours, and many 
victims of abuse never present as an emergency.9 10 Less 
than a quarter of such patients (24%) feel able to confide 
about abuse within the ED,7 and an excellent recent review 
highlighted a lack of privacy and confidentiality around 
disclosure in this setting.4 Some of the barriers to routine 
screening by healthcare staff in the ED include lack of 
experience, lack of time, concerns about the process 
of asking patients and uncertainty about the benefit of 
disclosure.11 Many of these barriers can potentially be 
addressed within other acute secondary care settings.11 12
We believe that the fracture clinic is an ideal site for 
identifying and helping vulnerable patients at risk of 
abuse. Not only are these patients likely to sustain a 
musculoskeletal injury,12 but these clinics provide access 
to a group of relatively young, fit patients who might not 
otherwise be involved with healthcare services. This raises 
the questions of whether patients are willing to disclose 
abuse in the busy fracture clinic setting and whether staff 
are equipped to manage such a disclosure.
We previously conducted a national survey of multidis-
ciplinary fracture staff awareness of IPV.13 Staff reported 
high rates of asking about abuse (72%, 75/104) when 
suspicious but a low prevalence of routine assessment 
(2%, 2/104).13 This is commonly seen in the literature in 
other secondary care settings.4 6
Our study also showed that the majority of orthopaedic 
staff felt it was important to ask about IPV (74%, 90/121) 
but had poor knowledge of how to manage a disclosure 
(24%, 29/121 knew about available support13), which 
again is a common finding.4 6
IPV in the fracture clinic has been the focus of Cana-
dian and international multicentre studies by Professor 
Bhandari’s group.14 15 They found a 12- month IPV 
prevalence of 16%–32% and a lifetime prevalence of 
35% among female participants.14 15 These studies have 
provided comprehensive evidence that patients do 
appear to be willing to disclose abuse within this setting 
but have focused mainly on female patients. They also 
demonstrated that 74% of both male and female respon-
dents in the fracture clinic setting agreed that fracture 
clinics were an appropriate place for healthcare staff to 
screen for IPV.16
To compare previous results to a UK population and 
in order to address the question of IPV prevalence in 
male IPV patients, we conducted a cross- sectional survey 
in three Scottish orthopaedic centres. The primary objec-
tive was to ascertain the prevalence of IPV among fracture 
clinic attendees for trauma over the past 12 months in a 
current relationship (‘current’ IPV). It was hypothesised 
that 12- month prevalence would be 15%–20% as for a 
comparable Canadian cohort.14
The secondary objectives were to assess the lifetime 
prevalence of IPV and to characterise this population 
in comparison to fracture clinic attendees who were not 
currently experiencing abuse. We also sought to explore 
whether there was any difference in frequency or type of 
IPV for male versus female participants, whether partici-
pants had been asked about abuse by staff and whether 




This was a cross- sectional questionnaire- based study of the 
prevalence of IPV in patients presenting to orthopaedic 
fracture clinics at three centres in Scotland, the UK, from 
October 2016 to January 2018.
Three centres across the country were chosen to 
provide a broad perspective of IPV in fracture clinic 
patients. These centres were a large university teaching 
hospital in Dundee, a district hospital in the affluent city 
of Perth and a rural hospital in Inverness within the Scot-
tish Highlands.
Recruitment & data collection
Participating clinics were chosen on a non- random 
basis according to the availability of the research team 
to provide support to fracture clinic staff should it be 
required. Data collection took place over the following 
dates:
 ► Centre 1: Ninewells Hospital (Dundee) from October 
2016 to October 2017.
 ► Centre 2: Perth Royal Infirmary (Perth) from January 
2017 to January 2018.
 ► Centre 3: Raigmore Hospital (Inverness) from April 
2017 to July 2017.
At each participating fracture clinic, all adult patients 
were given a questionnaire pack on checking into clinic. 
This pack contained the validated questionnaire (online 
Key messages
What is already known on this topic:
 ► Intimate partner violence (IPV) is common fracture clinic attenders, 
with 12- month prevalence rates of 15%–32% in female participants 
reported in the international literature.14 15
 ► Fracture clinic staff report high rates of asking about abuse (74%, 
77/104), but few are trained to deal with a disclosure of IPV.13
 ► No study to date has focused on the IPV rate in male participants in 
the fracture clinic setting, and this urgently needs to be remedied.
What this study adds:
 ► This study demonstrated that the IPV prevalence in fracture clinic 
patients was 12% within the past 12 months and had affected 20% 
of participants within their lifetime.
 ► Rates of abuse were comparable between male and female partic-
ipants, but a quarter of patients did not feel comfortable disclosing 
their gender.
 ► Only 5% of respondents had been asked about abuse in this study, 
which conflicts with previous evidence in the same centres suggest-
ing that staff routinely asked about abuse when suspicious.13
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supplemental figure 1) along with a participant informa-
tion sheet and information leaflet (online supplemental 
figure 2) detailing sources of advice and support for 
victims of IPV. Due to the desire to maintain anonymity 
in participants and stipulations in ethics committee 
approval, consent was presumed through completion of 
the anonymous questionnaire.
The questionnaire was a self- reported tool assessing 
multiple indicators of IPV previously validated in a multi-
centre study.15 The questionnaire contained several 
screening tools (the Woman Abuse Screening Tool 
(WAST) and the Partner Violence Screen)17 18 in addition 
to general questions about IPV and patient demographics 
including age, ethnicity, injury and sexual orientation. 
Participants were asked to describe their gender, and it 
was left to them to decide whether to identify based on 
biological or social preference.
The questionnaire pack could be completed and 
returned within the fracture clinic setting or taken home 
and returned via prepaid post. It was intended that any 
risk of coercion would be minimised as any patients who 
did not want to participate could simply return the blank 
questionnaire within the sealed envelope without the 
healthcare team’s knowledge.
Inclusion and exclusion criteria
All adult patients (man and woman) attending and 
participating fracture clinics were given questionnaire 
packs and were eligible to participate. During data 
analysis, respondents were excluded for age less than 
18 years old (zero participants) and for a non- trauma- 
related orthopaedic condition (elective patients, 60 
participants). Although not actively excluded, it is likely 
that patients who would not complete the questionnaire 
would include those who felt uncomfortable disclosing 
abuse within the fracture clinic setting, those who found 
the issue unimportant and those who were unable to 
read and write in English.
Outcomes
The primary outcome was the combined percentage of 
participants answering yes to the following question: ‘In 
your current relationship over the last 12 months, has 
your partner abused you physically/emotionally/sexu-
ally?’ (as per the WAST tool, these were asked as three 
separate questions). This was taken to indicate current 
IPV.
Secondary outcome measures included the combined 
percentage who answered yes to the following question: 
‘Have you ever been physically/emotionally/sexually 
abused by a partner?’ which was taken to indicate lifetime 
prevalence of IPV. All of the participants who had been 
abused within the past 12 months also reported that they 
had been abused within their lifetime with the exception 
of one, who left the entire second page blank. This has 
been reported as ‘unanswered’ in the analysis.
Sample size
Based on sample size calculations used in previous 
studies,14 15 an estimated 12- month IPV prevalence of 
15%–20% among fracture clinic attendees was chosen. 
With a confidence level of 95% and error margins of 
4–4.5, a sample size of 183–199 was required. This was 
rounded up to 250 to compensate for missing data. If true 
prevalence was much lower than 15%, a sample size of 
278 would provide 95% CIs with error margins of 1.58 
and was deemed acceptable.
Data analysis and missing data
Descriptive data are reported as frequencies and 
percentages for categorical variables within the dataset. 
Parametric data are presented as mean and SD and non- 
parametric as median and IQR. Where study groups have 
been directly compared with one another, dataset anal-
ysis comprised the χ2 test for categorical variables and 
Student’s t- test or non- parametric Wilcoxon test as appro-
priate for continuous variables (significance p<0.05).
Confidentiality
No screening of participant records took place to identify 
potential participants for the study. Fracture clinic recep-
tion staff handed out questionnaire packs to all adult 
patients attending and participating fracture clinics. 
Participation was entirely anonymous, with no way of 
contacting the patient or their general practitioner at a 
later date. This method was based on stipulations from 
ethics committee approval.
Regional ethics committee (REC) approval
The initial plan was to interview fracture clinic participants 
and gain formal consent as per a previous multicentre 
cross- sectional study recruiting in the USA, Canada and 
Europe11. The Prevalence of Abuse and Intimate Partner 
Violence Surgical Evaluation (PRAISE) Study screened 
fracture clinics for eligible patients and approached them 
to consider participation in the study when deemed safe 
to do so. The plan to repeat this method was given an 
unfavourable opinion at ethics committee review due to 
the perceived risk of patient harm by an abusive partner 
discovering that the participant had been selected out 
and approached for participation in the study. Under 
support from a second ethics committee, the study was 
redesigned. Participation was made completely anony-
mous with all clinic attendees given a questionnaire pack 
to consider participation without prior screening of clinic 
lists. A favourable opinion was granted by the North of 
Scotland REC on 31 August 2016 (Ref.: 16/NS/0078).
RESULTS
Demographics
Between October 2016 and January 2018, 61 clinics were 
used to hand out 524 questionnaires (figure 1). We are 
unable to provide details of non- respondents due to 
ethics committee stipulations, but all 61 clinics included 
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were non- specialist trauma clinics, with even recruitment 
by weekday and month (see online supplemental figure 
3). Three hundred ninety- six completed questionnaires 
were returned, generating a 76% response rate. Seven-
ty- two out of three hundred ninety- six (18%) question-
naires were returned by post, and of the remainder, there 
was an uneven spread between the three centres, with 
189 returned locally to centre 1 (47%), 27 to centre 2 
(7%) and 108 to centre 3 (27%). Although the planned 
sample size was 280, questionnaire packs were handed 
out in groups of 50 to participating fracture clinics, and 
those returned by post underwent some delay in collation 
and analysis. For this reason, recruitment was concluded 
at 396 respondents. This initial group included 60 partic-
ipants who were attending an orthopaedic clinic for 
an elective condition. These non- trauma patients were 
excluded from the main analysis but reviewed separately. 
The final trauma group numbered 336 participants.
Of the 336 orthopaedic trauma patients who partic-
ipated, 46% were women (156/336, table 1). Of the 
remaining half, 29% were men (99/336), and 24% did 
not disclose their gender (81/336). There was a range of 
ages among respondents with almost two- thirds over 40 
(63%, 212/336). Sixty- eight percent of participants were 
currently in a relationship (227/328, eight unanswered, 
median 16 years and IQR 5–34 years).
Orthopaedic trauma patient study population
Combined lifetime prevalence of IPV among respon-
dents was 20% (95% CI 16.1% to 24.9%, 68/336, 36 
unanswered). Sixty- seven participants had experienced 
emotional abuse (20%), 37 physical abuse (11%) and 15 
sexual abuse (4%, figure 2). Over the previous 12 months, 
10% of participants had experienced emotional abuse, 
4% physical abuse and 0.6% sexual abuse (34, 12 and 2, 
respectively, figure 3). The overall current prevalence of 
IPV violence was 12% (95% CI 8.4% to 15.5%, 39/336, 54 
unanswered).
Further comparison was made between two groups 
within the respondents, the ‘12- month IPV’ group (those 
who had experienced abuse within the past 12 months, 
39/336) and the ‘no recent IPV’ group (those who 
had not experienced abuse within the past 12 months, 
243/336) for the following analyses.
IPV study population
Age and gender were comparable between the 12- month 
IPV and no recent IPV groups, with 42% and 44% 
female gender (p=0.744) and 62% and 64% aged over 
41 (24/39 and 155/243, p=0.797), respectively (table 1). 
Also comparable between the IPV and non- IPV groups 
was country of birth, ethnicity, home circumstance, chil-
dren, education and sexual orientation (NS for all; see 
table 1). Compared with the non- IPV group, participants 
in the 12- month IPV group were more likely to describe 
some tension within their relationships (38%, 15/39, vs 
12%, 29/243, p<0.0001) and some difficulty in working 
out arguments (38%, 15/39, vs 12%, 29/243, p<0.0001). 
Arguments were more likely to result in hitting, kicking 
or pushing in the IPV group (10%, 4/39, vs zero in the 
non- IPV group, p<0.0001), and 4% felt frightened by 
their partner sometimes or often (23% 9/39 and 0.8%, 
2/243, respectively, p<0.0001).
Five percent (18/336) of all participants had previously 
been asked by healthcare staff about abuse (18%, 7/39, 
IPV group and 4%, 9/243, non- IPV group, p<0.001, 37 
unknown). Both groups felt that it was important to ask 
patients about abuse on a routine basis (79%, 31/39, 
and 69%, 168/243, respectively, p=0.355; 65%, 217/336 
overall, 39 blank).
Gender analysis
Since gender was undisclosed in a quarter of patients 
(22%, 75/336), the data for all participants, man and 
woman, have been presented for the 12- month IPV versus 
non- IPV group analyses.
There was no significant difference in IPV disclosure 
rates for lifetime IPV for female versus male patients 
(22%, 34/156 woman, and 16%,16/99 man, p=0.131, 
figure 4A). There was also no significant difference in 
prevalence by gender for 12- month IPV (11%, 17/156, 
and 10%, 10/99, respectively, p=0.420, figure 4B).
There was no difference in IPV disclosure rates for 
12- month IPV for female versus male patients (11%, 
17/156, and 10%, 10/99, respectively, p=0.420, figure 4A). 
There was also no significant difference in prevalence by 
gender for lifetime IPV (22%, 34/156 woman, and 16%, 
16/99 man, p=0.131, figure 4B). Comparison of type of 
IPV (emotional, physical or sexual) by gender of respon-
dent was made, and female respondents were significantly 
more likely to have experienced sexual abuse within their 
lifetime compared with male and gender- undisclosed 
participants (p=0.027, figure 5A). There were no signif-
icant differences in type of IPV by gender for 12- month 
abuse (figure 5B).
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Table 1 Table comparing demographic data for current intimate partner violence (IPV) (12- month IPV) and non- IPV groups
All 12- month IPV No recent IPV P value
Per 336 % Per 39 % Per 243 %
Gender
  Blank 81 24 12 31 63 26 0.744*
  Man 99 29 10 26 78 32
  Woman 156 46 17 44 102 42
Age
  Blank 8 2 0 0 6 2 0.797*
  16–25 45 13 4 10 25 10
  26–40 71 21 11 28 57 23
  41–60 115 34 16 41 89 37
  61 and over 97 3 8 21 66 27
Country of birth
  Blank 54 16 4 10 42 17 0.706*
  Scotland 198 59 29 74 136 56
  UK and others 64 19 5 13 51 21
  Europe 11 3 1 3 7 3
  Africa 4 1 0 0 3 1
  North America 2 0.6 0 0 2 0.8
  Asia 2 0.6 0 0 1 0.4
  Australasia 1 0.3 0 0 1 0.4
Ethnicity
  Blank 103 31 12 31 68 28 0.963*
  Asian 3 0.9 0 0 1 0.4
  Black British 2 0.6 0 0 1 0.4
  British/Scottish 103 31 11 28 80 33
Caucasian and others 117 35 15 38 86 35
  Mixed race 2 0.6 0 0 2 0.8
  Other unspecified 6 2 1 3 5 2
Home circumstance
  Blank 9 3 1 3 6 2 0.548*
  Alone 57 17 8 21 28 12
  Family 168 50 17 44 125 51
  Partner 92 27 12 31 79 33
  Friend/flatmate 6 2 0 0 2 0.8
  Student halls 3 0.9 1 3 2 0.8
  Care home 1 0.3 0 0 1 0.4
Children
  Blank 15 4 0 0 10 4 0.218*
  No 106 32 7 18 74 30
  Yes, they live with me 114 34 17 44 85 35
  Yes, they don’t live with me 101 30 15 38 74 30
Education
  Blank 25 7 1 3 17 7 0.316*
  Rather not say 10 3 0 0 9 4%
  High school 101 30 8 21 72 30
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All 12- month IPV No recent IPV P value
Per 336 % Per 39 % Per 243 %
  University 93 28 13 33 67 28
Sexual orientation
  Blank 15 4 0 0 10 4 0.300*
  Rather not say 3 0.9 0 0 3 1
  Heterosexual 306 91 37 95 222 91
  Bisexual 6 2 2 5 4 2
  Homosexual/gay 6 2 0 0 4 2
How would you describe your relationship generally?
  Blank/not in relationship 119 35 14 36 51 21 <0.0001*
  No tension 172 51 9 23 163 67
  Some tension 44 13 15 38 29 12
  A lot of tension 1 0.3 1 3 0 0
How do you and your partner work out arguments?
  Blank/not in relationship 115 34 13 33 49 20 <0.0001*
  With no difficulty 174 52 10 26 165 68
  With some difficulty 44 13 16 41 29 12
  With great difficulty 3 0.9 0 0 0 0
Do arguments result in you feeling down or bad about yourself?
  Blank/not in relationship 105 31 9 23 42 17 <0.0001*
  Never 158 47 6 15 152 63
  Sometimes 69 21 20 51 49 20
  Often 4 1 4 10 0 0
Do arguments ever result in hitting, kicking or pushing?
  Blank/not in relationship 105 31 9 23 42 17 <0.0001*
  Never 227 68 26 67 201 83
  Sometimes 3 0.9 3 8 0 0
  Often 1 0.3 1 3 0 0
Do you ever feel frightened by what your partner says/does?
  Blank/not in relationship 107 32 11 28 42 17 <0.0001*
  Never 218 65 19 49 199 82
  Sometimes 10 3 8 21 2 0.8
  Often 1 0.3 1 3 0 0
Have you been asked by staff about domestic abuse?
  Blank 37 11 0 0 8 3 0.0005*
  Yes 281 84 7 18 9 4
  No 18 5 32 82 226 93
Should healthcare staff routinely ask patients with fractures about domestic abuse?
  Blank 39 12 1 3 7
3%
0.355*
  Yes 74 22 31 79 168 69
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Elective orthopaedic patients
Sixty participants attending for elective conditions with no 
history of trauma returned completed questionnaires but 
were analysed separately (see Methods section). Gender 
was comparable in this group to the trauma group (53% 
woman, 32/60, and 28% man, 17/60, compared with 
61% woman, 156/255 known, and 39% man, 99/255 
known, respectively). The elective patients had a higher 
overall age, with 87% over 40 (52/60) compared with 
63% (212/336) in the trauma group. Elective ortho-
paedic patients had a significantly lower rate of current 
IPV compared with trauma patients (5%, 3/60, vs 12%, 
39/336, p=0.025, figure 6).
DISCUSSION
The 12- month prevalence of IPV among fracture clinic 
attenders in this study of three Scottish trauma units was 
12%, and lifetime prevalence was 20%. Although over a 
fifth did not disclose their gender, there was no signif-
icant difference between rates of current IPV among 
female and male participants (22% and 16%, respec-
tively) and lifetime IPV (11% and 10%, respectively). 
The majority of IPV disclosed was emotional abuse, 
with physical and sexual abuse less likely to be reported, 
a trend seen in the majority of centres in the PRAISE 
Multicentre IPV Study15 (table 2 and figure 7). As can 
be seen from figure 7, the prevalence of IPV within Scot-
land is comparable to current and lifetime IPV rates in 
other European countries like Denmark and the Neth-
erlands. The 12% 12- month prevalence of IPV seen in 
our study is significantly lower than that seen in the 
USA and earlier Canadian studies (p<0.0001 for both, χ2 
test). It should be noted that the difference in recruit-
ment methods used between our study and the PRAISE 
study should lead to caution in making direct compar-
isons between prevalence rates of IPV compared with 
our population. Our response rate of 76% is lower than 
the 85% reported by the PRAISE investigators,19 which 
Figure 2 ‘Have you ever been physically/emotionally/
sexually abused by a partner?’ bar chart showing lifetime 
prevalence of intimate partner violence in orthopaedic trauma 
patients. Of 68/336 participants (20%) who disclosed having 
been abused by a partner at some point in their lives, 67 
had experienced emotional abuse (20%), 37 physical abuse 
(11%) and 15 sexual abuse (4%).
Figure 3 (Over the last 12 months) ‘Has your partner 
abused you physically/emotionally/sexually?’ bar chart 
showing 12- month or current prevalence of intimate partner 
violence in orthopaedic trauma patients (primary aim of 
study). Thirty- nine out of three hundred thirty- six participants 
(12%) had been abused by a partner at some point within 
the past 12 months. Of these, 34 had experienced emotional 
abuse (10%), 12 physical abuse (4%) and two sexual abuse 
(0.6%).
Figure 4 Bar charts demonstrating prevalence of 
intimate partner violence (IPV) by gender (man, woman or 
undisclosed). (A) Lifetime prevalence of IPV by gender. There 
was no significant difference between female and male 
participants who disclosed previous abuse (22%, 34/156, 
and 16%, 16/99, respectively, p=0.131, χ2 test). (B) Twelve- 
month or current prevalence of IPV by gender. There was no 
significant difference between female and male participants 
who disclosed current abuse (11%, 17/156, and 10%, 10/99, 
respectively, p=0.420, χ2 test). NS: ‘not significant’ = p>0.05.
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is perhaps unsurprising given the difference in recruit-
ment methods (face- to- face questionnaire in PRAISE 
compared with anonymous questionnaire completion in 
this study), but we have already reported evidence that 
patients may prefer anonymised questionnaire formats 
in identifying domestic abuse.4 8
It should be noted that the WAST screening tool used in 
this study identifies abuse in somewhat general terms (see 
online supplemental figure 1). It is possible that partic-
ipants could answer yes to some of the questions and 
be incorrectly identified as suffering from abuse, partic-
ularly emotional abuse. However, we used the question 
‘has your partner abused you physically/emotionally/
sexually’, which will allow the participants to determine 
whether they are being subjected to IPV or not.
The gender spread and trend towards age over 40 in our 
participant population were comparable to the general 
fracture population within the UK.20 This allows us some 
confidence in extrapolating our results to the general 
fracture clinic population, within the limits of the lack of 
data on response rates, which was a limitation of the study 
design (see Limitations and future work section).
None of the injuries in this study were due to IPV, 
despite the relatively high prevalence of current abuse 
within the group. This may reflect the high rates of 
emotional abuse and low rates of physical abuse disclosed 
by participants and is supported by the literature, which 
suggests that rates of physical and sexual violence are 
higher in female victims of IPV (compared with hetero-
sexual male victims) but that rates of emotional, coercive 
and controlling abuse appear to be equally prevalent and 
may even be more commonly reported by male victims14.
The final aim was to establish whether, as reported in 
our previous study,13 orthopaedic staff ask trauma patients 
about IPV and whether they are educated and equipped 
to manage a disclosure of abuse. In the current study, 
only 5% of our participants reported having been asked 
about IPV by healthcare staff, although 59% felt that it 
was important to ask about abuse routinely. It is worth 
noting that in a questionnaire where a large number of 
questions were left blank by participants (see table 1), 
the response rate for these two questions was very high 
at 97%.
Low rates of healthcare staff enquiry about abuse are 
well documented, reported by 16% of abused participants 
within the Canadian IPV Study and 14% in the PRAISE 
trial.14 15 It is clear that if staff are not routinely asking about 
abuse (even in patients who are suffering from IPV), this 
will translate to fewer at- risk patients being identified and 
a missed opportunity for helping this vulnerable group. 
In a study of prevalence of IPV in ED trauma clinics, of 
the 12% of participants who disclosed abuse within this 
setting, two- thirds (63%) were sent home without a safety 
assessment and 79% without input from social services.21
The justification for orthopaedic fracture clinics as a 
potential site for identifying and intervening in the care 
of these patients has been well established.9 13 22 Evidence 
from this study and previous studies does seem to suggest 
that patients are willing to disclose abuse within this 
setting, but previous work suggests that up to 50% of 
patients would not make a disclosure unless asked directly 
Figure 5 Bar charts demonstrating type of intimate partner 
violence (IPV) including physical, emotional and sexual abuse 
by gender (man, woman or undisclosed). (A) Lifetime type of 
IPV by gender. Female respondents were significantly more 
likely to report sexual IPV (p=0.027, χ2 test). All genders 
were equally likely to report physical and emotional IPV 
(p=0.151 and p=0.992, respectively, χ2 test). (B) Twelve- month 
type of IPV by gender. There were no significant differences 
in type of IPV by gender for physical, emotional or sexual IPV 
(p=0.718, p=0.536 and p=0.673, respectively, χ2 test).
Figure 6 Bar chart showing prevalence of 12- month 
or current intimate partner violence (IPV) in the group 
of orthopaedic trauma patients (trauma group) versus a 
separate group of elective orthopaedic patients (elective 
group). Participants within the trauma group were more likely 
to be suffering from current IPV than elective participants 
(12%, 39/336, and 5%, 3/60, respectively, p=0.025).
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in the presence of a physician or senior healthcare staff 
member.7 14
This is the first study worldwide to investigate the prev-
alence of IPV among male orthopaedic trauma patients. 
The large number of participants who did not disclose 
their gender (22%) suggests there is ongoing difficulty in 
admitting to domestic violence in relation to gender, and 
we have chosen to analyse participants en masse to avoid 
unfair exclusion of this large group of participants whose 
gender is undisclosed. In this study, we found no significant 
difference in 12- month or lifetime prevalence between 
male or female participants. It is unknown whether the 
reasons for non- disclosure of IPV (and, indeed, gender 
in this study) vary between male and female patients. It is 
possible that a number of participants chose to leave this 
section blank as they did not identify as male or female, 
and it is important to recognise that the reported rate of 
IPV is high among transgender individuals.23 Future work 
should incorporate patient feedback, explicitly including 
male and female patients, regarding barriers to disclosure 
of abuse within the secondary care setting.22
Finally, we chose to focus on the fracture clinic popula-
tion for this prevalence study to provide insight on IPV in 
a population of young, otherwise fit patients who might 
not otherwise present to healthcare services on a regular 
basis. For this reason, the 60 participants with elective 
orthopaedic conditions were excluded from the primary 
analysis. Although not formally powered, the elective 
subgroup analysis did demonstrate a population of ortho-
paedic patients with a higher average age and lower rate 
of IPV compared with trauma patients (5% and 12% 
12- month IPV prevalence, respectively, p<0.0001, χ2 test).
Limitations and future work
There is the risk of selection bias in the study group due 
to recruitment through orthopaedic fracture clinics, 
which tend to see patients who are younger and fitter 
than the general population.20 24 The current and lifetime 
IPV prevalence reported in this paper should be consid-
ered therefore to apply to the Scottish fracture clinic 
Table 2 Table comparing intimate partner violence (IPV) prevalence across different countries as published by Bhandari et al14 
and the Prevalence of Abuse and Intimate Partner Violence Surgical Evaluation investigators15 (female participants only) with 
the data from this study (female and male participants).
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Figure 7 Forest plot showing prevalence of intimate partner 
violence by country based on data (female participants only) 
published by Bhandari et al14and the Prevalence of Abuse 
and Intimate Partner Violence Surgical Evaluation (PRAISE) 
investigators.15 ES: effect size.
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population, and caution should be used in applying this 
to the general public.
In addition, this study contains limited data on response 
rates and composition of participating fracture clinics 
due to restrictions placed by the ethics committee during 
review for the purposes of protecting the safety of vulner-
able participants. It is therefore not within the scope of 
this study to comment on how many patients given the 
anonymous questionnaire packs were willing to complete 
these within the setting, and we can only comment on 
the responses received. It is possible that the results are 
subject to selection bias (patients who do not consider 
the issue important/relevant to them may not partici-
pate) or that patients who are being abused are less likely 
to participate due to fear of their abuser finding out. If 
this is the case, then the true prevalence of IPV may be 
much higher than that reported in this study.
Participants within the 12- month IPV group were more 
likely to have been asked by healthcare staff about abuse 
than the non- IPV group (18% and 4%, respectively). 
Although this may reflect recall bias, published evidence 
does suggest that healthcare staff are more likely to 
enquire about abuse in those deemed at high risk.4 13 22 
However, there is an increasing call for routine enquiry 
when screening for abuse to occur in acute situations like 
the fracture clinic to identify those suffering from occult 
or ‘incidental abuse’ (not related to the current presen-
tation).25 Indeed, none of the 39 participants currently 
being abused in this study had presented with an injury 
related to abuse, and many would likely be considered 
‘low risk’ by staff. We would recommend that staff in acute 
settings (such as trauma) should consider enquiring 
about abuse in every patient on a routine basis to reduce 
stigma, identify occult cases and increase healthcare staff 
awareness on this vital topic.25
It should be noted that this study covers IPV exclusively, 
without covering other methods of domestic violence 
such as abuse by a family member. The questionnaire 
used in this study was designed to detect IPV only, but 
any healthcare staff education should cover other types of 
domestic violence to maximise the number of vulnerable 
populations that can be identified by an increased rate of 
awareness of this issue.
Finally, it should be noted that this study was not 
powered to detect lifetime prevalence of IPV. With esti-
mated lifetime rates of 16%–53% in the literature,14 15 a 
significantly larger sample size (approximately 700–1000 
participants) would be required to power such a study. 
As such, our lifetime IPV prevalence should be consid-
ered as the basis for future work to validate this estimate. 
In addition, the current study is not powered to investi-
gate the role of patient characteristics (eg, gender and 
education) in identifying those at increased risk of abuse 
via multivariate analysis. This again is not the objective of 
this study as the increasing emphasis in the literature is 
to screen all patients including those perceived to be at 
‘low risk’ (such as male patients) in an effort to improve 
rates of identification; reduce stigma; and prevent rare, 
significant complications such as significant injury and 
murder.4 5
IMPLICATIONS
In summary, IPV was common in the three orthopaedic 
fracture clinics who participated in this study, with a 12% 
12- month and 20% lifetime prevalence. Although the 
true rate of IPV may be much higher, patients do appear 
to be willing to make a disclosure of abuse within this 
setting. Rates of abuse were not significantly different 
between male and female participants, but a quarter of 
patients did not feel comfortable disclosing their gender.
Despite 74% of orthopaedic healthcare staff reporting 
that they would ask about abuse in trauma patients,13 only 
5% of patients overall report having been asked about 
abuse in this study.
Evidence from the literature and this study suggests that 
the orthopaedic fracture clinic is an appropriate place to 
identify those at risk of abuse, and we would recommend 
that training needs to be made available to ensure that 
healthcare staff know the benefits of routine enquiry and 
are equipped to manage a disclosure of IPV. In addition, 
it is vital that screening does not just involve staff ‘just 
asking the questions’ but about creating a supportive 
environment where patients can disclose safely and staff 
are adequately trained to support individuals.26–28
Future work should focus on whether increased aware-
ness and better training can lead to increased rates of 
abuse identification, better care and reduced risk to this 
vulnerable group. We do not wish to add to the work of 
busy fracture clinics, but with a lifetime prevalence of one 
in five and a current prevalence of one in eight in both 
men and women, our staff need to at least be aware of this 
issue and how to manage it.
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Have you been hit, kicked, punched or hurt by anyone  in the past year? Yes No 
If so, what is their relationship to you? 
Partner Ex-partner Family member Other (please explain) 
  
If yes, have you told anyone about this? 
  
In your current relationship, over the last 12 months… 
How would you describe your relationship generally? A lot of tension Some tension No tension 







Do arguments ever result in you feeling put down or bad 
about yourself? 
Often Sometimes Never 
Do arguments ever result in hitting, kicking or pushing? Often Sometimes Never 
Do you ever feel frightened by what your partner says/does? Often Sometimes Never 
Has your partner abused you physically? Often Sometimes Never 
Has your partner abused you emotionally? Often Sometimes Never 
Has your partner abused you sexually? Often Sometimes Never 
  
Have you ever been physically abused by a partner? Yes No 
Have you ever been emotionally abused by a partner? Yes No 
Have you ever been sexually abused by a partner? Yes No 
If yes, have you told anyone about this? 
  
Is your current injury the result of abuse from a partner? Yes No 
Have you ever been asked by a doctor, nurse or any healthcare professional about 
domestic abuse? 
Yes No 




Is there anything else you’d like to state or add which you have not addressed above? 
 
If you have any questions, please contact one of the numbers on the patient 
information sheet or speak to one of the clinic nurses 
Thank you for participating – we are really grateful for your time and help. 
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PARTICIPANT INFORMATION SHEET 
NHS [ HEALTH BOARD ] 
  
Dear Fracture Clinic Attender: 
We would like to invite you to take part in a research study, which will help us to 
identify how common domestic abuse is amongst patients with orthopaedic injuries.  
Our study is entitled: “How common is domestic abuse (also known as 
intimate partner violence) in orthopaedic trauma?” 
  
We are inviting you to take part because you are a patient who has an appointment at 
fracture clinic for a trauma-related injury.  We are giving out questionnaires to all 
patients over the age of 16, males and females.  Our aim is to recruit 800 patients in 
total between NHS Tayside and NHS Highland. 
  
What will I have to do if I take part? 
If you agree to take part, please read this information sheet before completing the 
questionnaire provided.  You can either deposit the questionnaire into the secure box 
here in clinic (specify location) or return it by post using the envelope provided to the 
following address:  
[ LOCAL COLLABORATOR NAME AND ADDRESS ]. 
The results are completely anonymous and we have no way of contacting you once 
you complete the questionnaire. 
  
Do I have to take part? 
It is up to you to decide whether to participate in the study, you are free to refuse to 
take part or change your mind.  You don’t have to give a reason for refusal and this 
will not affect your orthopaedic care or treatment.  Once you have completed the 
questionnaire and deposited it within the secure box, there is no way to identify you or 
remove your data from the study. 
  
What are the risks of taking part?  
You may find it distressing to answer some of the questions – if you do not like any of 
the questions asked, feel free not to answer them.  You can also stop completing the 
questionnaire at any time if you change your mind.  In addition, there is a nurse 
available who is not involved in the study who will be happy to provide support and 
sit with you while you complete the questionnaire.  Just ask one of the fracture clinic 
nurses if you would like this. 
  
How will you protect my privacy and confidentiality? 
We do not take any details such as your name or address and have no way of 
contacting you after you leave the clinic today.  The results of the study will be 
completely anonymous and your consultant will not know whether you have 
participated in the study or not. 
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Who has reviewed the study? 
The project is sponsored by NHS Tayside and the University of Dundee and funded 
by Tayside Health Board Endowment Fund.  The North of Scotland Research Ethics 
Committee (1) has reviewed this study and has raised no objections from the point of 
view of medical ethics.  It is a requirement that records of this research may be made 
available for review by monitors from NHS Tayside and the University of Dundee. 
  
What if there is a problem? 
If you have any concerns or a complaint about your participation in the study, you 
should first talk to a researcher involved in the study.  However, you also have the 
right to raise a formal complaint.  You can make a complaint to a senior member of 
the research team, [ LOCAL COLLABORATOR NAME AND TELEPHONE] or to 
the Complaints Officer for NHS Tayside: 
Complaints and Feedback Team 
The Business Unit, Level 7, Laboratory Corridors B & F 
Ninewells Hospital, Dundee DD1 9SY 
Freephone: 0800 027 5507 
Email: feedback.tayside@nhs.net   
In the event that you think you have suffered harm as a result of your participation in 
the study, there are no automatic financial compensation arrangements.  However, you 
may have the right to make a claim for compensation against the University of 
Dundee or NHS Tayside.  Where you wish to make a claim, you should consider 
seeking independent legal advice but you may have to pay for your legal costs. 
   
What will happen to the results of the research study? 
These results will be presented anonymously at medical meetings and may be 
published in a medical journal.  They will hopefully guide our care of future patients 
and help us to develop a better support system for victims of domestic violence. 
  
Where do I go for further information? 
If you have any questions or concerns about the issues raised in this questionnaire, 
you can approach any of the fracture clinic staff in confidence or email the researchers 
on: orthopaedics.study@gmail.com.  Fracture clinic staff can contact one of the 
researchers if you want to ask any further questions.  You should also have received 
an information leaflet with your questionnaire.  
  
If you do not feel safe to go home, the clinic staff can help you get in touch with 
the [ LOCAL ] Police Domestic Abuse Liaison officer (101) or [ LOCAL ] 
Women’s Aid [ TELEPHONE ] for advice and refuge. 
If you would like more support, your GP or Social Work Department can help or 
you can telephone the Domestic Abuse Helpline (0808 2000 247) 24 hours a day. 
 
Thank you for your help in this important research.  Yours sincerely, 
 
Mr Arpit Jariwala 
Chief Investigator 
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Supplemental Figure 3 
Table providing available data on participating fracture clinics.  Due to ethics committee 
stipulations, we are unable to provide detailed data on fracture clinic makeup or any data on 
patients who declined to participate. 
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